دورية أكاديمية
أعرض في EDS

Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans .

التفاصيل البيبلوغرافية
العنوان: Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans .
المؤلفون: Faria DR; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Melo RC; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Arita GS; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Sakita KM; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Rodrigues-Vendramini FAV; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Capoci IRG; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Becker TCA; Laboratory of General Pathology, Department of Basic Health Sciences, State University of Maringá, Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Bonfim-Mendonça PS; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Felipe MSS; Program of Genomic Sciences and Biotechnology, Catholic University of Brasilia, Brasília 70790-160, Brazil., Svidzinski TIE; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil., Kioshima ES; Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil.
المصدر: Pathogens (Basel, Switzerland) [Pathogens] 2021 Mar 07; Vol. 10 (3). Date of Electronic Publication: 2021 Mar 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101596317 Publication Model: Electronic Cited Medium: Print ISSN: 2076-0817 (Print) Linking ISSN: 20760817 NLM ISO Abbreviation: Pathogens Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2012-
مستخلص: Candida albicans is the most common species isolated from nosocomial bloodstream infections. Due to limited therapeutic arsenal and increase of drug resistance, there is an urgent need for new antifungals. Therefore, the antifungal activity against C. albicans and in vivo toxicity of a 1,3,4-oxadiazole compound (LMM6) was evaluated. This compound was selected by in silico approach based on chemical similarity. LMM6 was highly effective against several clinical C. albicans isolates, with minimum inhibitory concentration values ranging from 8 to 32 µg/mL. This compound also showed synergic effect with amphotericin B and caspofungin. In addition, quantitative assay showed that LMM6 exhibited a fungicidal profile and a promising anti-biofilm activity, pointing to its therapeutic potential. The evaluation of acute toxicity indicated that LMM6 is safe for preclinical trials. No mortality and no alterations in the investigated parameters were observed. In addition, no substantial alteration was found in Hippocratic screening, biochemical or hematological analyzes. LMM6 (5 mg/kg twice a day) was able to reduce both spleen and kidneys fungal burden and further, promoted the suppresses of inflammatory cytokines, resulting in infection control. These preclinical findings support future application of LMM6 as potential antifungal in the treatment of invasive candidiasis.
References: Med Mycol. 2012 Jan;50(1):33-42. (PMID: 21756200)
Toxicol Pathol. 2007 Aug;35(5):751-5. (PMID: 17849358)
Sci Rep. 2019 Nov 15;9(1):16905. (PMID: 31729441)
Future Microbiol. 2016 Aug;11:1035-46. (PMID: 27501739)
Clin Microbiol Infect. 2008 May;14 Suppl 4:65-70. (PMID: 18430131)
Int J Mol Sci. 2019 Jun 06;20(11):. (PMID: 31174387)
Chem Biol Interact. 2020 Jan 5;315:108896. (PMID: 31743685)
Molecules. 2019 Jan 06;24(1):. (PMID: 30621357)
Mycoses. 2016 Nov;59(11):678-690. (PMID: 27061755)
Antimicrob Agents Chemother. 2017 Feb 23;61(3):. (PMID: 28069658)
Clin Infect Dis. 2009 May 15;48(10):1441-58. (PMID: 19361301)
Infect Dis (Lond). 2018 Mar;50(3):214-219. (PMID: 28988525)
J Hosp Infect. 2018 Jul;99(3):318-324. (PMID: 29522784)
Adv Clin Chem. 1965;8:141-87. (PMID: 5321443)
Front Microbiol. 2019 Sep 12;10:2130. (PMID: 31572335)
J Clin Med. 2019 Sep 20;8(10):. (PMID: 31547077)
PLoS One. 2014 Jan 22;9(1):e85836. (PMID: 24465737)
Front Microbiol. 2016 Feb 09;7:113. (PMID: 26903992)
Nat Rev Dis Primers. 2018 May 11;4:18026. (PMID: 29749387)
Front Microbiol. 2017 Jan 12;7:2173. (PMID: 28127295)
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:5-10. (PMID: 24506442)
Biochem Pharmacol. 2017 Jun 1;133:86-96. (PMID: 27884742)
Front Microbiol. 2018 Jun 04;9:1196. (PMID: 29915571)
J Infect Dis. 2005 Jul 15;192(2):336-43. (PMID: 15962230)
Clin Lab Med. 2011 Mar;31(1):161-72. (PMID: 21295728)
J Clin Med Res. 2017 Jun;9(6):451-456. (PMID: 28496543)
Rev Iberoam Micol. 2009 Dec 31;26(4):223-7. (PMID: 19836985)
Int J Nephrol Renovasc Dis. 2014 Dec 12;7:457-68. (PMID: 25540591)
Jundishapur J Microbiol. 2016 Sep 26;9(11):e37385. (PMID: 28138373)
Phytomedicine. 2018 Feb 1;40:55-58. (PMID: 29496175)
Antimicrob Agents Chemother. 2017 Sep 22;61(10):. (PMID: 28784671)
Br J Haematol. 2005 Jun;129(5):583-96. (PMID: 15916680)
Clin Infect Dis. 2016 Feb 15;62(4):e1-50. (PMID: 26679628)
Mycology. 2018 Jan 09;9(2):116-128. (PMID: 30123667)
J Fungi (Basel). 2021 Feb 02;7(2):. (PMID: 33540778)
J Innate Immun. 2011;3(2):180-99. (PMID: 21063074)
Med Mycol. 2015 Sep;53(7):656-65. (PMID: 26162470)
Dtsch Arztebl Int. 2019 Apr 19;116(16):271-278. (PMID: 31159914)
PLoS One. 2020 Jan 14;15(1):e0227876. (PMID: 31935275)
Curr Drug Metab. 2017;18(6):556-565. (PMID: 28302026)
Eur J Med Chem. 2018 Jan 20;144:255-261. (PMID: 29274492)
Transpl Infect Dis. 2015 Apr;17(2):308-13. (PMID: 25726707)
Antimicrob Agents Chemother. 1997 Jun;41(6):1392-5. (PMID: 9174207)
Biomed Rep. 2015 Mar;3(2):179-182. (PMID: 25798245)
PLoS Negl Trop Dis. 2019 Jun 4;13(6):e0007441. (PMID: 31163021)
J Ethnopharmacol. 2019 May 23;236:42-49. (PMID: 30771517)
Lancet. 2019 Nov 23;394(10212):1949-1964. (PMID: 31777389)
PLoS One. 2015 Nov 16;10(11):e0142926. (PMID: 26569405)
Ann Intensive Care. 2019 Jun 3;9(1):62. (PMID: 31161475)
Mini Rev Med Chem. 2019;19(6):477-509. (PMID: 30324877)
J Antimicrob Chemother. 2003 Jun;51(6):1427-9. (PMID: 12716772)
Front Microbiol. 2019 Sep 06;10:2071. (PMID: 31555252)
mBio. 2015 Jun 23;6(3):e00647. (PMID: 26106079)
Bioinformatics. 2016 Sep 15;32(18):2866-8. (PMID: 27153664)
Eur J Biochem. 2000 Oct;267(20):6102-9. (PMID: 11012661)
J Appl Physiol. 1950 Dec;3(6):365-77. (PMID: 14794596)
Front Microbiol. 2017 Jan 23;8:36. (PMID: 28167935)
معلومات مُعتمدة: 552276/2011-1 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 88882.449039/2019-01 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
فهرسة مساهمة: Keywords: 1,3,4-oxadiazole; Candida albicans; antifungal agents; biofilm; candidiasis; drug discovery; drug resistance; toxicity
تواريخ الأحداث: Date Created: 20210403 Latest Revision: 20210413
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8001722
DOI: 10.3390/pathogens10030314
PMID: 33800117
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-0817
DOI:10.3390/pathogens10030314